Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 7Completed 6Active not recruiting 3Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 4Glioblastoma 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Brain Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Gliosarcoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Skin Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Pain 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1

Interventions

nimotuzumab 4Paclitaxel 3Surgical Procedures, Operative 2Cisplatin 2sintilimab 1pembrolizumab 1monalizumab 1epacadostat 1Taxes 1TP protocol 1Saline Solution 1Radiation 1Oxaliplatin 1Nimodipine 1Metabolic Networks and Pathways 1Fluorouracil 1Biopsy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Esophageal Squamous Cell Carcinoma × Radiation × Clear all
NCT02272699 2021-03-18

Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Peking University

Phase 2/3 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡